Shuttle Pharmaceuticals (SHPH) Stock Dips Despite Patent News

Shuttle Pharmaceuticals (SHPH) shares saw a dip despite receiving a new patent for its selective histone deacetylase (HDAC) inhibitors. The patent covers inhibitors designed to fight cancer and other diseases. Despite earlier gains, the stock is currently trading lower. Benzinga explores the factors investors should consider when evaluating SHPH as a potential investment.

Scroll to Top